Top Quality Deoxo-9a-aza-9a-homoerythromycin A CAS NO (76801-85-9) For Sale

Here's a comprehensive description for Deoxo-9a-aza-9a-homoerythromycin A (76801-85-9):

1. Introduction to Deoxo-9a-aza-9a-homoerythromycin A (76801-85-9) Deoxo-9a-aza-9a-homoerythromycin A is a semi-synthetic macrolide antibiotic derived from erythromycin A. It belongs to the subclass of macrolide antibiotics known as azalides. This compound exhibits potent antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria, making it valuable in the treatment of various infectious diseases.

2. Chemical Structure and Molecular Composition The molecular formula of deoxo-9a-aza-9a-homoerythromycin A is C38H68N2O12, representing a complex macrocyclic lactone ring structure with an additional nitrogen atom incorporated into the macrocycle. This modification alters the pharmacological properties of the parent compound, enhancing its stability, bioavailability, and spectrum of activity against resistant bacterial strains.

3. Synthesis and Production Deoxo-9a-aza-9a-homoerythromycin A is synthesized through chemical modification of erythromycin A using appropriate reagents and reaction conditions. The addition of an aziridine ring to the macrocycle introduces the nitrogen atom, resulting in the formation of the azalide derivative. Commercially, it may be produced on a laboratory scale for research purposes or on an industrial scale for pharmaceutical applications.

4. Mechanism of Action Similar to other macrolide antibiotics, deoxo-9a-aza-9a-homoerythromycin A exerts its antibacterial effects by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and disrupting bacterial growth and replication. The incorporation of the aziridine ring enhances the stability of the compound and its affinity for the ribosome, leading to improved bactericidal activity.

5. Spectrum of Activity Deoxo-9a-aza-9a-homoerythromycin A exhibits a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative bacteria. It is effective against pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Legionella pneumophila, among others. Its potency and extended half-life contribute to its efficacy in the treatment of various infections.

6. Pharmacokinetics and Metabolism Following oral or parenteral administration, deoxo-9a-aza-9a-homoerythromycin A is rapidly absorbed and distributed to various tissues and body fluids, achieving therapeutic concentrations at the site of infection. It undergoes hepatic metabolism, primarily by cytochrome P450 enzymes, to form inactive metabolites that are excreted via renal and biliary routes. The pharmacokinetic profile of deoxo-9a-aza-9a-homoerythromycin A allows for convenient dosing regimens and sustained antibacterial activity.

7. Clinical Applications Deoxo-9a-aza-9a-homoerythromycin A is used in the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, genitourinary tract infections, and gastrointestinal infections. It is available in oral and parenteral formulations for ease of administration and can be prescribed for both outpatient and inpatient settings, depending on the severity of the infection and patient factors.

8. Safety and Adverse Effects Deoxo-9a-aza-9a-homoerythromycin A is generally well tolerated when administered at recommended doses. However, adverse effects such as gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), hepatotoxicity, allergic reactions, and cardiac arrhythmias may occur in some individuals. Patients with known hypersensitivity to macrolide antibiotics should avoid its use, and caution is advised in patients with pre-existing liver or cardiac conditions.

9. Resistance and Antimicrobial Stewardship As with any antibiotic, the emergence of antimicrobial resistance is a concern with deoxo-9a-aza-9a-homoerythromycin A. Prudent use of antibiotics, including deoxo-9a-aza-9a-homoerythromycin A, in accordance with established guidelines and principles of antimicrobial stewardship, is essential to minimize the development and spread of resistant bacterial strains. Regular surveillance of bacterial susceptibility patterns and judicious use of antibiotics can help preserve the efficacy of deoxo-9a-aza-9a-homoerythromycin A for future generations.

10. Research and Future Perspectives Ongoing research efforts focus on optimizing the pharmacological properties, dosage regimens, and treatment protocols for deoxo-9a-aza-9a-homoerythromycin A, as well as exploring its potential in the management of emerging bacterial pathogens and antibiotic-resistant infections. Collaborative initiatives between researchers, clinicians, and pharmaceutical companies are essential to address current challenges and advance the field of antibiotic therapy.

In conclusion, deoxo-9a-aza-9a-homoerythromycin A represents a valuable addition to the arsenal of antibiotics available for the treatment of bacterial infections. Its unique chemical structure, broad spectrum of activity, and favorable pharmacokinetic profile make it a promising candidate for the management of various infectious diseases. However, responsible use and antimicrobial stewardship are crucial to ensure the continued efficacy of deoxo-9a-aza-9a-homoerythromycin A and other antibiotics in the fight against antimicrobial resistance.